Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

King Pharmaceuticals, Inc.

http://www.kingpharm.com

Latest From King Pharmaceuticals, Inc.

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies

AbbVie Ups Efforts In HS And Advances Lutikizumab Into Phase III

There are a raft of investigational products looking to move into the rapidly growing hidradenitis suppurativa market and AbbVie is hoping to grab a decent share with two assets, the anti-interleukin-1 alpha and beta monoclonal antibody lutikizumab and its anti-inflammatory blockbuster Rinvoq.

Dermatology Clinical Trials

Eisai And Eli Lilly Triumph At The 19th Annual Scrip Awards

Eisai and Lilly were the biggest winners at the 19th Annual Scrip Awards in a glittering ceremony at the Dorchester in London’s Mayfair, hosted by the actor and comedian Jon Culshaw.

Companies Commercial

Jefferies Conference Highlights How Biotech’s Rollercoaster Ride Will Continue Into 2024

Survey shows long-term optimism but fears that 2024 will be another hard slog for those biotechs with dwindling cash resources.

Commercial Companies
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Alpharma Inc.
UsernamePublicRestriction

Register